Amgen Inc. (AMGN) announced promising topline results from its Phase 3 trial of TEPEZZA, a treatment for moderate-to-severe Thyroid Eye Disease (TED), using a subcutaneous injection method via an on-body injector. The trial demonstrated a significant 77% proptosis response rate at 24 weeks, compared to just 19.6% in the placebo group, along with a mean proptosis reduction of -3.17 mm versus -0.80 mm for placebo. These results affirm TEPEZZA’s effectiveness, building on its previous intravenous formulation approved in 2020.
This development is crucial for Amgen as it reinforces TEPEZZA’s position in the market, potentially enhancing revenue streams from a treatment that addresses a serious and rare autoimmune condition. The positive trial results could lead to increased investor confidence, particularly as the company continues to innovate in the biotech space.
For market professionals, the key takeaway is that Amgen’s ongoing success with TEPEZZA may bolster its stock performance and provide a competitive edge in the biotechnology sector, particularly as it expands treatment options for TED.
Source: nasdaq.com